-
公开(公告)号：US20110039802A1
公开(公告)日：2011-02-17
申请号：US12830282
申请日：2010-07-02
IPC分类号： A61K31/695 , C07C311/46 , A61K31/18 , C07C313/06 , A61K31/165 , C07D265/30 , A61K31/5375 , C07D209/48 , A61K31/4035 , C07D211/06 , A61K31/4453 , C07D209/88 , A61K31/407 , C07D241/04 , A61K31/495 , C07D403/04 , A61K31/506 , C07D215/14 , A61K31/47 , C07D233/68 , A61K31/4164 , C07F7/18 , A61P3/04
CPC分类号： C07D249/08 , A61K31/00 , A61K31/18 , A61K31/341 , A61K31/351 , A61K31/357 , A61K31/37 , A61K31/381 , A61K31/4015 , A61K31/402 , A61K31/4035 , A61K31/41 , A61K31/4196 , A61K31/42 , A61K31/421 , A61K31/423 , A61K31/425 , A61K31/428 , A61K31/433 , A61K31/44 , A61K31/4409 , A61K31/4453 , A61K31/451 , A61K31/495 , A61K31/4965 , A61K31/505 , A61K31/5375 , A61K31/63 , A61K31/635 , C07C311/06 , C07C311/07 , C07C311/08 , C07C311/14 , C07C311/20 , C07C311/21 , C07C311/46 , C07C323/40 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07C2602/10 , C07C2602/44 , C07C2603/18 , C07D207/09 , C07D207/12 , C07D207/16 , C07D209/08 , C07D209/48 , C07D209/88 , C07D211/58 , C07D211/62 , C07D213/75 , C07D213/82 , C07D215/36 , C07D215/38 , C07D217/04 , C07D219/10 , C07D231/12 , C07D231/16 , C07D231/56 , C07D233/56 , C07D233/68 , C07D239/42 , C07D277/56 , C07D277/70 , C07D285/06 , C07D295/135 , C07D307/68 , C07D307/91 , C07D311/16 , C07D317/66 , C07D333/38 , C07D333/72
摘要： The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound of the formula (I): wherein R1 is lower alkyl, cycloalkyl or the like, R2 is hydrogen, lower alkyl or the like, n is 1 or 2, X is lower alkylone, lower alkenylene, arylene, cycloalkylene or the like, Y is CONR7, CSNR7, NR7CO, NR7CS or the like, Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like and R7 is hydrogen or lower alkyl, prodrug, pharmaceutically acceptable salt or solvate thereof
摘要翻译： 本发明提供一种用作NPY Y5受体拮抗剂的药物组合物，其包含式（I）化合物：其中R 1为低级烷基，环烷基等，R 2为氢，低级烷基等，n为1或 2，X为低级烷基，低级亚烯基，亚芳基，亚环烷基等，Y为CONR7，CSNR7，NR7CO，NR7CS等，Z为低级烷基，任选取代的碳环基，任选取代的杂环基等，且R7为氢或 低级烷基，前药，药学上可接受的盐或溶剂化物
-
公开(公告)号：US20100292500A1
公开(公告)日：2010-11-18
申请号：US12830272
申请日：2010-07-02
IPC分类号： C07C61/09 , C07C229/28
CPC分类号： C07D249/08 , A61K31/00 , A61K31/18 , A61K31/341 , A61K31/351 , A61K31/357 , A61K31/37 , A61K31/381 , A61K31/4015 , A61K31/402 , A61K31/4035 , A61K31/41 , A61K31/4196 , A61K31/42 , A61K31/421 , A61K31/423 , A61K31/425 , A61K31/428 , A61K31/433 , A61K31/44 , A61K31/4409 , A61K31/4453 , A61K31/451 , A61K31/495 , A61K31/4965 , A61K31/505 , A61K31/5375 , A61K31/63 , A61K31/635 , C07C311/06 , C07C311/07 , C07C311/08 , C07C311/14 , C07C311/20 , C07C311/21 , C07C311/46 , C07C323/40 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07C2602/10 , C07C2602/44 , C07C2603/18 , C07D207/09 , C07D207/12 , C07D207/16 , C07D209/08 , C07D209/48 , C07D209/88 , C07D211/58 , C07D211/62 , C07D213/75 , C07D213/82 , C07D215/36 , C07D215/38 , C07D217/04 , C07D219/10 , C07D231/12 , C07D231/16 , C07D231/56 , C07D233/56 , C07D233/68 , C07D239/42 , C07D277/56 , C07D277/70 , C07D285/06 , C07D295/135 , C07D307/68 , C07D307/91 , C07D311/16 , C07D317/66 , C07D333/38 , C07D333/72
摘要： The present invention provides a pharmaceutical composition for use as art NPY Y5 receptor antagonist comprising a compound or the formula (I): wherein R1 is lower alkyl, cycloalkyl or the like, R2 is hydrogen, lower alkyl or the like, n is 1 or 2, X is lower alkylene, lower alkenylene, arylene, cycloalkylene or the like, Y is CONR7, CSNR7, NR7CO, NR7CS or the like, Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like and R7 is hydrogen or lower alkyl, prodrug, pharmaceutically acceptable salt or solvate thereof.
摘要翻译： 本发明提供一种用作本领域的NPY Y5受体拮抗剂的药物组合物，其包含化合物或式（I）：其中R 1为低级烷基，环烷基等，R 2为氢，低级烷基等，n为1或 2，X为低级亚烷基，低级亚烯基，亚芳基，亚环烷基等，Y为CONR7，CSNR7，NR7CO，NR7CS等，Z为低级烷基，任选取代的碳环基，任选取代的杂环基等，而R7为氢或 低级烷基，前药，药学上可接受的盐或溶剂化物。
-
![Process for the Manufacture of the Calcium Salt of Rosuvastatin (E)-7-[4-(4-Fluorophenyl)-6-Isopropyl-2-[Methyl(Methylsulfonyl)Amino]-Pyrimidin-5-yl](3R,5S)-3,5-Dihydroxyhept-6-Enoic Acid and Crystalline Intermediates Thereof](/abs-image/US/2011/12/08/US20110301348A1/abs.jpg.150x150.jpg)
3.发明申请Process for the Manufacture of the Calcium Salt of Rosuvastatin (E)-7-[4-(4-Fluorophenyl)-6-Isopropyl-2-[Methyl(Methylsulfonyl)Amino]-Pyrimidin-5-yl](3R,5S)-3,5-Dihydroxyhept-6-Enoic Acid and Crystalline Intermediates Thereof 审中-公开罗苏伐他汀（E）-7- [4-（4-氟苯基）-6-异丙基-2- [甲基（甲基磺酰基）氨基] - 嘧啶-5-基]（3R，5S）的钙盐的制造方法 -3,5-二羟基庚-6-烯酸及其结晶中间体公开(公告)号：US20110301348A1
公开(公告)日：2011-12-08
申请号：US13186363
申请日：2011-07-19
IPC分类号： C07D407/06 , C07D239/69
CPC分类号： C07D239/42 , C07D405/06 , Y02P20/55
摘要： A process for the manufacture of the calcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid, useful as an HMGCoA reductase inhibitor, from a compound of the formula (7) wherein A is an acetal or ketal protecting group and R is alkyl, via isolated crystalline compounds of the formula (8) or of formula (10) is described. Crystalline intermediates of formulae 7, 8 and 10 are also described.
摘要翻译： （E）-7- [4-（4-氟苯基）-6-异丙基-2- [甲基（甲基磺酰基）氨基]嘧啶-5-基]（3R，5S）的钙盐的制备方法 由式（7）的化合物（其中A是缩醛或缩酮保护基，R是烷基）用作HMGCoA还原酶抑制剂的3,5-二羟基庚-6-烯酸经由分离的式（8）的结晶化合物 ）或式（10）。 还描述了式7,8和10的结晶中间体。
-
-
搜索结果
3 条记录 (耗时 0.021 秒)
